Reuters |
GSK, Theravance's Breo Faces Scrutiny Over Safety for Asthma
Bloomberg (Bloomberg) — GlaxoSmithKline Plc and Theravance Inc.'s respiratory drug Breo Ellipta will face questions from a regulatory panel over the safety of expanding its use to treat asthma patients and whether it's suitable for children. Advisers to the U.S … FDA staff finds no new safety problems with Glaxo's asthma drug GSK Studies Found No Asthma Deaths For COPD Drug, FDA Says New Glaxo asthma treatment reviewed by FDA |
View full post on asthma – Google News